EMA says Ozempic, Wegovy is linked to rare cases of eye disorders – Country
The European Medicines Agency's Safety Committee concluded that Novo Novo's popular weight loss medication and its treatment for type 2 diabetes may lead to rare potentially dangerous eye conditions.
The disease is known as non-limb ischemic neuropathy (NAION), and the condition may affect up to 10,000 people taking the active ingredients of semaglutide, Wegovy and Novo's diabetes drugs Ozempic and Rybelsus, while Rybelsus may affect one person.
The EMA began reviewing in December and said the risk of drug use and development status increased by about two times compared to those who did not take the medication.
NAION flows from insufficient blood to the optic nerve and causes sudden painless vision loss in one eye. Due to optic nerve damage, this is the second most common cause of blindness caused by glaucoma.
Past research links semaglutide to past larvae. But this is the first time that regulators have established links.
Get weekly health news
Receive the latest medical news and health information every Sunday.
Semi-deli foods belong to a class of drugs called GLP-1 receptor agonists, which work by helping to control blood sugar levels and trigger a sense of fullness.
A large number of studies of nearly 350,000 diabetics published earlier this year show that the risk of developing larvae more than doubled after long-term use of Semirubide compared to taking other classes of medications.
EMA said it has reviewed all available data about NAIN, including data from non-clinical studies, clinical trials and post-market monitoring.
It advised the pharmacist to update the prescription information for the drug containing semaglutide to use NAION as a side effect, with a frequency of “very rare”.
The U.S. Food and Drug Administration did not immediately respond to Reuters' request for comment.
